Reversal of Skin Aging with Topical Retinoids

Special Topic Reversal of Skin Aging with Topical Retinoids Bradley A. Hubbard, M.D. Jacob G. Unger, M.D. Rod J. Rohrich, M.D. Dallas, Texas

Summary: Topical skin care and its place in plastic surgery today are often overlooked by clinicians formulating a plan for facial rejuvenation. Not only is it important to consider topical skin care as part of comprehensive care, but clinicians should also be educated with the data available in today's literature. This review aims to familiarize the reader with the biological processes of skin aging and evidence-based clinical outcomes afforded by various topical therapies. Furthermore, this review will focus on solar damage, the value of retinoids, and how they can be used in conjunction with forms of treatment such as chemical peel, dermabrasion, and lasers. Finally, guidelines will be provided to help the physician administer appropriate skin care based on the data presented. (Plast. Reconstr. Surg. 133: 481e, 2014.)

T

he pursuit to prevent or reverse human aging is as old as time itself. The shelves of pharmacies, department stores, and physicians’ offices are filled with a dizzying array of topical products aimed at skin rejuvenation. Unfortunately, the role of topical skin care is often overlooked, or worse, poorly understood by the plastic surgery community. This review aims to familiarize the reader with the biological processes of skin aging and evidence-based clinical outcomes afforded by topical retinoid therapy.

PHOTOAGING OF SKIN Molecular Level Ultraviolet radiation causes direct and indirect damage to skin. Direct damage results from absorption of the ultraviolet energy by DNA. Although ultraviolet B (290 to 320 nm) is most likely to induce pyrimidine base changes, ultraviolet A (320 to 400 nm) can also cause direct damage.1 Defects in mitochondrial DNA impair oxidative phosphorylation, leading to further oxidative stress on the entire cell.2 Although nuclear and mitochondrial DNA are affected, mitochondrial DNA repair mechanisms are less efficient and therefore more susceptible to permanent damage.

Although ultraviolet A can directly induce DNA changes, most of its cell damage is indirect through the creation of reactive oxygen species and free radicals. Cells are designed to tolerate From the Department of Plastic Surgery, University of Texas Southwestern Medical Center.

Received for publication March 14, 2013; accepted August 13, 2013.

Copyright © 2014 by the American Society of Plastic Surgeons DOI: 10.1097/PRS.0000000000000043

an oxidative environment and protect themselves with DNA repair enzymes, enzymatic reduction proteins, and antioxidants.2 However, high metabolic demand, ultraviolet radiation, smoking, decreased cellular function with age, and other factors may overwhelm the system and oxidative damage results.

Clinical Findings On a clinical level, the most common finding in naturally aged skin that has been protected from exposure to ultraviolet light is thin, dry, smooth, and unblemished skin. Photoaged skin (skin that has had marked exposure to ultraviolet light), in contrast, is characterized by fine and coarse wrinkles, roughness, laxity, sallowness, scaling, dryness, telangiectasia, and dyschromia (Fig. 1, left). There is also an increased frequency of benign, premalignant, and malignant lesions.3,4 Seborrheic keratoses are commonly associated with sun-exposed, aged skin.5 Histologic Findings Epidermis Aged photoprotected epidermis is usually thin, with decreased cellular turnover. There are minor abnormalities in keratinocyte maturation but a normal stratum corneum, in addition to a flattened contour of the rete pegs, increasing fragility, and susceptibility to shear stress forces (Fig. 2, above).5 Disclosure: None of authors has any commercial associations or financial disclosures that might pose or create a conflict of interest with information presented in this article.

www.PRSJournal.com

481e

Plastic and Reconstructive Surgery • April 2014

Fig. 1. Clinical photographs of photodamage pretreatment. (Left) Fine and coarse wrinkles, roughness, laxity, sallowness, scaling, telangiectasia, and dyschromia. (Center) After 1 year of nightly tretinoin 0.05% cream. (Right) After 5 years.

Photodamaged keratinocytes are characterized by atypia, loss of polarity (nonorderly maturation), slowed proliferation, and lessened cell signaling and response.6–8 Histologically,

Fig. 2. Photodamaged skin and photoprotected skin histology. (Reproduced with permission from Singh M, Griffiths CE. The use of retinoids in the treatment of photoaging. Dermatol Ther.

2006;19:297–305.)

482e

the epidermal thickness is increased in unprotected skin. However, concomitant flattening of the rete ridges can give the appearance of decreased thickness or atrophy (Fig. 2, below).6 On the whole, melanocytes decrease in number, have shortened lifespans, and respond less to growth factors, resulting in guttate hypomelanosis.9 However, there can also be regions of increased melanocyte concentration, increased capacity for melanin production, and increased melanin deposition into keratinocytes (e.g., solar lentigines).5 Dermis Of note, ultraviolet B light is almost completely absorbed by the epidermis; thus, dermal photodamage is caused solely by ultraviolet A light. In photoprotected skin, there is a decrease in all cell type density and extracellular matrix contents.

Collagen, elastin, glycosaminoglycan content, and fibroblast and Langerhans cell counts are all decreased.10 Photoaged dermis on the cellular level is marked by signs of chronic inflammation. Fibroblasts and Langerhans cells are decreased and surrounded by abundant inflammatory infiltrate, a condition termed heliodermatitis.11,12 Fibroblasts are morphologically abnormal and produce less collagen.

Solar elastosis is the term used to describe the histologic appearance of the photoaged dermal

Volume 133, Number 4 • Topical Retinoids for Skin Aging extracellular matrix. This condition is characterized by an accumulation of amorphous, abnormal elastin material surrounding a decreased volume and disorganized array of wavy collagen fibrils.3,6 It is hypothesized that the abnormal elastin results from overproduction of normal elastin, which is subsequently degraded by the chronic inflammatory state.3 The other major components of extracellular matrix (glycoproteins and glycosaminoglycans) tend to diminish with age but are increased in photoaged skin.13 However, the increased glycosaminoglycans are not found in the papillary dermis and epidermis as usual; instead, they are deposited in the reticular dermis within the elastotic material.14 In this location, the glycosaminoglycans are not able to regulate hydration, leading to dry and leathery appearing skin.15

RETINOID THERAPY Retinoids are a family of compounds composed of vitamin A, its derivatives, and synthetic molecules acting through the same pathway.

Since the 1940s, they have been used topically and orally for a multitude of skin conditions (primarily, acne). Retinoids’ ability to rejuvenate photoaged skin was popularized in the 1980s, in large part because of the work of Kligman et al.16–18 Classification of the retinoid family can be done using their chemical makeup (presence of aromatic groups), generation, natural or synthetic, and prescription or over-the-counter availability. Table 1 displays an exhaustive list of retinoids using many existing classifications.19 Table 1. Classification of Retinoids Generation

Retinoid

First (nonaromatic and naturally ­occurring)

Retinol (all-trans-retinol, vitamin A)† Retinyl-palmitate† Retinyl-propionate† Retinyl-retinoate† Retinyl N-formyl aspartamate† Retinyl-acetate† Retinaldehyde† Tretinoin (all-trans-retinoic acid)*† Isotretinoin (13-cis-retinoic acid)*† Alitretinoin (9-cis-retinoic acid)*† Second Etretinate‡ ­(monoaromatic) Acetretin* Third (polyaromatic) Adapalene*† Tazarotene*† Bexarotene* Fourth (pyranones) Seletinoid G*† Arotinoid* Eretin*

*Prescription only. †Studied for effects on skin aging. ‡U.S. Food and Drug Administration approval retracted.

Mechanism of Action Retinols are naturally existing elements acquired through diet. Retinol (vitamin A) is absorbed through the small intestine and transported to be stored as a retinol ester (palmitate, propionate, and acetate) or oxidized to tretinoin through a two-step process, with retinaldehyde serving as the intermediate. Tretinoin represents 50 percent of the active cellular form, with its metabolites (4-hydroxy-retinoic acid) and stereoisomers 9-cis-retinoic acid (alitretinoin) and 13-cis-retinoic acid (isotretinoin) making up the difference.20 Thus, in topical application, retinol, retinol esters, and retinaldehyde have to be converted to a more active form (tretinoin), whereas isotretinoin, alitretinoin, adapalene, tazarotene, and seletinoid G are applied in their active form.

Histologic Retinoid Effects Retinoids increase collagen content in the upper papillary dermis by inhibiting collagen degradation and increasing collagen synthesis. Topical tretinoin application before ultraviolet irradiation has been shown to prevent matrix metalloproteinase production and collagen degradation.21 New type I procollagen biosynthesis is increased by retinoids.22,23 Histologically, increased collagen types I, III, and VII (dermal-epidermal anchoring fibrils) can be seen, as can reorganization of the dermal collagen into new woven bundles.24 Topical tretinoin has been shown to increase production of type I collagen by 80 percent in photoaged skin.25 It is thought that the increased collagen content indirectly stimulates normalization of the elastic tissue organization.26 Increased smoothness of skin or wrinkle effacement from tretinoin topical treatment results from epidermal hyperplasia, compaction of the stratum corneum, thickening of the granular layer, and increased epidermal and dermal glycosaminoglycan deposition. Tretinoin therapy has also been shown to improve wound healing.

This is most likely the effect of improved cutaneous circulation, which has been demonstrated by laser Doppler velocimetry.27 Animal studies have also shown tretinoin to have an effect on cytokeratin 16, which is an important modulator of the wound healing process.28 However, to date, a direct ­cause-and-effect relationship has not been established.

Tretinoin Clinical Evidence The typically studied treatment protocol is 0.05% tretinoin cream applied nightly. Using this

483e

Plastic and Reconstructive Surgery • April 2014

Fig. 3. (Above, left) Photodamaged skin before tretinoin treatment. (Above, right) Photodamaged skin after 4 months of topical tretinoin treatment. Keratinocytes are more organized, the granular layer thickness is increased, the stratum corneum is more compact, and severe elastosis continues to be present.

(Below) Photoaged skin after 9 months of topical tretinoin treatment. There is restoration of polarity, thickening of the granular layer, increased angiogenesis in the dermis, and decreased elastosis. (Slides reprinted with permission from Torras H. Retinoids in aging. Clin Dermatol. 1996;14:207–215.)

protocol, epidermal thickening and improvement in fine wrinkles may be seen as soon as 3 months (Level II Evidence).29,30 After 6 months of therapy, improvements in fine and coarse wrinkling, sallowness, dyschromia, roughness, and laxity have been observed (Level I Evidence).31–35 However, at 6 months, improvement is limited to the epidermis, as no changes in dermal collagen or elastosis were seen (Figs. 1, center, and 2, above, right). Bhawan et al. confirmed that dermal changes were not seen at 6 months, and continued treatment for 12 months, at which point formation of new collagen fibers and reduction in elastoic material was seen (Figs. 1, right, and 3, below).36 The optimal dosing of tretinoin is a balance between efficacy and side effects, known as the retinoid reaction. The retinoid reaction consists of erythema, scaling, xerosis, and pruritus. These side effects are dose dependent. They are seen in the majority of patients using 0.05% concentrations daily and in upward of 90 percent of patients treated with 0.1% concentrations. However, the side-effect severity tends to subside over time.29 To reduce the incidence or severity of the retinoid reaction, several studies have been performed

484e

with lower concentrations of tretinoin. After 6 months of therapy, two large, ­vehicle-controlled, double-blind, randomized trials have shown superior epidermal improvement using a 0.05% concentration compared with 0.01%.32,33 Griffiths et al. compared 0.1% and 0.025% concentrations in a similarly designed study over 8 months and found no statistically significant difference in epidermal changes. Not surprisingly, the 0.025% concentration had far fewer adverse effects.37 Thus, it appears that concentrations of 0.025% to 0.1% have equivalent efficacy for epidermal improvement at 6 to 8 months.

Lower concentrations of tretinoin have also been studied with longer treatment durations.

Olsen and colleagues followed 298 patients randomized to daily application of 0.05%, 0.01%, or vehicle for 11 months. Statistical improvement over the vehicle preparation was identical for both tretinoin concentrations in clinical and histologic evaluations.38 Similarly, Nyirady et al. performed a double-blind, ­vehicle-controlled comparison of 0.02% and 0.05% tretinoin cream for 24 months and found no statistically significant difference in clinical improvement.39 Thus, these studies have

Volume 133, Number 4 • Topical Retinoids for Skin Aging indicated that with prolonged therapy there may not be any advantage to using treatments with higher concentration levels.

Because of the delayed gratification of clinical improvement and concurrent incidence of adverse effects, patient noncompliance and discontinuation of therapy are not uncommon with tretinoin therapy. This has stimulated investigation of high-strength tretinoin treatment. Kligman and colleagues have been the strongest proponents of this style of therapy. In 1998, their group studied 50 women using 0.25% tretinoin cream every other night for 2 weeks followed thereafter by nightly application. Not only did they find the therapy to be well tolerated by patients, but also the clinical and histologic improvement after 4 to 6 weeks was similar to their results of patients who underwent 12 months of 0.05% daily application.

Specifically, fine wrinkling, hyperpigmentation, elasticity, hydration, vascularity, and new collagen deposition were witnessed.40 In 2004, Kligman and Draelos studied 32 women with 0.25% tretinoin for 4 weeks. Again, early onset of epidermal and dermal changes was witnessed, in a process they have termed “rapid retinization.” Perhaps more interesting, the retinoid reaction was markedly diminished within only 2 weeks of treatment.41 To date, randomized controlled trials using rapid retinization concepts have yet to be performed.

The safety and efficacy of a lifetime prescription of tretinoin are less well understood, as no study to date has greater than 6-year follow-up.

After 48 months of 0.05% cream, Olsen et al. randomized 126 patients to once-weekly application, three-times-weekly application, or discontinuation of therapy. Three-times-weekly therapy was found to preserve fine wrinkle improvement better than once-weekly therapy. Discontinuation of therapy resulted in significant reversal of the antiaging effect.42 Therefore, discontinuation or significant truncation of tretinoin therapy appears to result in reversal of effect to some extent.

Ellis et al. followed patients for 22 months using 0.1% and 0.05% concentrations. Their firstyear results were similar to the above-noted studies.

However, epidermal thickness decreased gradually from its 6-month peak (although it was greater than before treatment), mitotic figures decreased, and the compact stratum corneum reverted to its pretreatment basket-weave pattern.43 A 4-year study of patients using variable concentrations of tretinoin, but all using 0.025% for the last 19 months, found slightly different results. Epidermal thickness did decrease slightly between 1 and 4 years, but the granular layer thickness and stratum corneum

compaction were unchanged.44 Lastly, Kligman et al. followed patients for 5 to 6 years using 0.05% concentration daily. In this group of patients, they found continued improvement over time in the dermis and epidermis. Specifically, they found a widening Grenz layer, decreased elastotic tissue, increased fibroblast density, and decreased dermal glycosaminoglycan.45 No conclusion can be drawn as to the best maintenance therapy dosing or concentration of tretinoin. Current evidence regarding the long-term effect of tretinoin on epidermal thickness and compaction of the stratum corneum is contradictory. However, evidence does suggest that continued tretinoin therapy is necessary to prolong, maintain, or possibly improve on early clinical gains in dyschromia and reversal of solar elastosis.

Isotretinoin Molecular/Histologic Evidence Isotretinoin (13-cis-retinoic acid) is a stereoisomer of retinoic acid. It is known to bind to cellular retinoic acid–binding protein intracellularly and bind all retinoic acid receptor subtypes directly.

However, some debate exists as to whether its topical effect is, in some part, attributable to conversion to tretinoin in vivo.46 Clinical Evidence The clinical evidence for the effect of isotretinoin on photoaging is less than that of tretinoin but nonetheless significant. Three groups have performed large (n = 776, n = 326, and n = 800) double-blind, vehicle-controlled, randomized trials using 0.1% cream for 9 months.47–49 All demonstrated statistically significant clinical improvement in wrinkling pigmentation, sallowness, and texture compared with controls starting at 12 weeks. However, no significant changes were found in the dermis in terms of elastosis reduction or fibroblast density. It should be noted that the duration of each study was only 9 months; thus, long-term dermal effects are unknown. Side effects were local and severe in only 5 to 10 percent. Plasma concentration of isotretinoin was not increased over the 36-week study period.

Alirezai et al. studied the effect of twice-daily 0.1% isotretinoin cream on actinic keratoses.50 In a vehicle-controlled study, two-thirds of patients were found to have a greater than 33 percent reduction in precancerous growths in 6 months.

More recently, oral isotretinoin therapy has been investigated for efficacy in the treatment of photoaging. Although there was some early level II evidence of subjective clinical improvement,

485e

Plastic and Reconstructive Surgery • April 2014 Bagatin et al. have recently called these results into question with better controls and objective assessment measures.51–53 In their 2010 phase II trial, 32 women were randomized to sunscreen and moisturizer, or 20 mg of isotretinoin orally three times per week plus sunscreen and moisturizer. The oral isotretinoin group was found to have no clinical benefit on profilometry, corneometry, skin elasticity tests, or histologic examination. In addition to the significant side-effect and safety concerns associated with oral isotretinoin therapy, current evidence is discouraging for the efficacy of oral isotretinoin in facial aging.

Retinol (Vitamin A) Molecular/Histologic Evidence Retinol is commonly used as a component in cosmeceutical products. Its potential in the treatment of antiaging was realized in 1995, when Kang et al. first showed the ability of retinol to induce epidermal thickening with little irritation.

The drastic reduction in the retinoid reaction is attributable to the replacement of retinoic acid’s carboxyl group with a hydroxyl group. Unfortunately, retinol is very unstable when exposed to light, oxygen, heat, lipid-peroxidation, and water, reducing its bioavailability.54 Furthermore, retinol must be converted to tretinoin in vivo to become biologically active.55 From these shortcomings, it has been speculated that retinol is 20-fold less effective than tretinoin, and the dermal concentration of tretinoin is 1000-fold less than that seen when topically applying the proper drug.56 Some have hypothesized that if retinol were applied at concentrations high enough to have similar effects as tretinoin, the side-effect profile would be similar.

Clinical Evidence To date, evidence on the use of retinol in photoaged skin is limited to small controlled trials of limited duration. Piérard-Franchimont et al. conducted the first controlled clinical trial with retinol and demonstrated significant improvement in fine wrinkles after 12 weeks of treatment.57 Varani and colleagues studied 1% retinol on 53 patients with photoaged skin compared with a vehicle control. They found statistically significant histologic improvement at 7 days.58 Kafi et al. conducted a randomized, double-blind, vehicle-controlled study of 0.4% retinol in the upper arm skin of 23 patients. They found significant improvement in subjective fine wrinkles and histologic improvement.59 It should be noted that the commonly researched retinol concentrations range from

486e

0.4% to 1%, compared with the average over-thecounter products, which contain 0.08% or less.60 Retinyl Esters and Derivatives Molecular/Histologic Evidence Like retinol, its esters and derivatives must undergo in vivo conversion to the active form, tretinoin. Their creation has been stimulated by the side effects of tretinoin therapy and the instability of retinol.

Clinical Evidence Retinyl propionate was the first clinically studied retinol ester. Green et al. conducted a double-blind, randomized, placebo-controlled ­ trial with 80 patients using retinyl propionate cream. Fifty-nine patients completed the 48-week study. No subjective or objective data suggested improvement compared with the vehicle control.61 Retinyl palpitate was studied indirectly by Watson et al., who compared commercially available skin creams; one contained retinyl palmitate (concentration, <0.2%). They concluded that it was unclear whether retinyl palmitate was responsible for any of the favorable histologic changes witnessed.62 Retinyl N-formyl aspartamate is a photostable and temperature-stable retinol derivative. In a prospective trial, 24 Korean women’s faces had twice-daily applications of an unknown concentration of retinyl N-formyl aspartamate on one facial half and a vehicle control on the other. Although not randomized and lacking power, statistically significant improvement in objective and subjective skin surface characteristics were found, with only one patient reporting skin irritation.63 Most recently, the photostable retinyl retinoate has been investigated. Retinyl retinoate is a synthetic retinoid that combines retinol and retinoic acid molecules with an ester bond. In a small (n = 46) randomized controlled trial, 0.06% retinyl retinoate was compared with 0.075% retinol over 3 months. Statistically significant improvement was found in subjective and objective surface characteristics, without any reported skin irritation.64 Retinaldehyde Molecular/Histologic Evidence Retinaldehyde is the naturally occurring intermediate compound formed when retinol is oxidized to tretinoin through a two-step process.

Thus, like the other retinol esters, its clinical activity depends on in vivo conversion to tretinoin.

Intrinsic to the retinaldehyde molecule is an

Volume 133, Number 4 • Topical Retinoids for Skin Aging antibacterial and comedolytic effect, but this has yet to be proven in an in vivo model.65 Clinical Evidence In the group of retinol esters and derivatives, retinaldehyde has the greatest evidence for reversal of skin aging. In a randomized controlled trial of 229 volunteers using the forearm model, morphologic changes from 0.5% retinaldehyde and 0.1% tretinoin were similar.66 Creidi et al. conducted a similar randomized trial with 125 patients, comparing 0.05% retinaldehyde, 0.05% tretinoin, and vehicle. Retinaldehyde and tretinoin had similar improvements on profilometric scores at 18 and 44 weeks, although retinaldehyde was better tolerated throughout the study period.67 The evidence supporting retinaldehyde for the reversal of photodamaged skin is promising, although long-term trials with histologic evidence against tretinoin therapy still need to be performed.

COMPLICATIONS As discussed previously, the most common complication and reason for noncompliance is the retinoid reaction. It is much more common in tretinoin and tazarotene because of their exposed carboxylic acid group. Accordingly, local irritation is relatively uncommon with isotretinoin, adapalene, retinol, retinaldehyde, and other synthetic derivatives.68 In the majority of cases, the retinoid reaction occurs early in treatment and resolves gradually. It was originally believed that the erythematous reaction was required and related directly to the improvements seen in photoaged skin, much like topical 5-fluorouracil therapy. However, the cause of retinoid actions on keratinocytes and other dermal cells has been found independent of the inflammatory state.

The most important predictive feature of those likely to suffer retinoid reaction is sensitive skin. These “sensitive skin” patients have been outlined by Kligman as follows: Fitzpatrick type 1 skin, historical intolerance of other topicals (e.g., perfumes, sunscreens, or astringents), people who blush or feel hot after embarrassment, skin chronically exposed to large amounts of cosmetics, or skin with other dermatologic disease (e.g., eczema, rosacea, or seborrheic dermatitis).69 Commonly used strategies to reduce the retinoid reaction are dermal moisturization (at least 30 minutes after retinoid application) and a gradual introduction to retinoid therapy (lower concentrations or less frequent application). Conversely, Kligman et al. promote high-concentration retinoid treatment, which in their experience has more rapid accommodation to local side effects.40,41

Concomitant application of other medications and naturally occurring compounds has also been advocated for reduction of local side effects.

Although treating a medication side effect with another medication is less than desirable, 3% indomethacin and/or 1% hydrocortisone have been described to treat the severely affected.70 Lastly, the vehicle with which retinoids are delivered through the epidermis has a powerful effect on the local side effects. Leyden et al. studied the commonly used delivery vehicles for tazarotene, adapalene, and tretinoin.71 They found microsponge gel for tretinoin, cream for tazarotene, and gel for adapalene to be the least reactive vehicles for each retinoid. More recently, liposome and nanoparticle carriers have been studied, mostly in animal models.

Nanoparticle delivery systems have shown the most promise, by not only decreasing local side effects but also significantly increasing drug efficacy.72 Photosensitivity is the other commonly associated side effect of topical retinoid therapy. Much like the retinoid reaction, photosensitization normally occurs at the beginning of therapy and resolves after several months.70 Patients are advised to avoid excessive sun exposure and include daily sunscreen application to their skin care regimen.

Systemic side effects have not been reported in the three decades of topical retinoid use.

Although teratogenicity of topical retinoid use has not been reported, pregnant patients should be advised to discontinue use because of the lack of concrete evidence. Interestingly, one retrospective case control study of 215 mothers exposed to tretinoin in the first trimester had lower rates of birth defects than the control group (1.9 percent versus 2.6 percent, respectively).73

RETINOIDS IN WOUND HEALING Chemical Peel In a randomized controlled trial, Hevia et al. studied pretreatment with 0.1% tretinoin cream 2 weeks before a 35% trichloroacetic acid peel of the arms and face. Tretinoin sites displayed earlier, more intense and uniform frosting, because of the compacted stratum corneum. In addition, the pretreated group had a statistically significant increase in the area of reepithelialized skin after 1 week.74 Dermabrasion Mandy studied pretreatment with 0.5% tretinoin cream for 2 weeks before full- or half-face dermabrasion for acne scarring. Compared with the control group, pretreated faces completely

487e

Plastic and Reconstructive Surgery • April 2014 reepithelialized 2 days earlier (Level I Evidence).75 In addition, pretreated patients suffered less postinflammatory hyperpigmentation and had no milia formation.

Laser Encouraged by the results from pretreating patients before chemical peels and microdermabrasion, animal studies were performed to evaluate the role of retinoid before carbon dioxide laser resurfacing. Using a guinea pig model, McDonald et al. demonstrated faster reepithelialization and more rapid healing. Theoretically, retinoid pretreatment would decrease postoperative milia, decrease postoperative hyperpigmentation, and increase laser penetration through the thinner stratum corneum.76 These beliefs were so well accepted that a survey of the American Society for Laser Medicine and Surgery showed that 80 percent of dermatologists and plastic surgeons recommended treatment with retinoids before carbon dioxide laser resurfacing.77 In 2004, Orringer et al. challenged these beliefs. They studied carbon dioxide resurfacing for photodamaged forearm skin after 3 weeks of pretreatment with 0.05% tretinoin cream or vehicle control. No benefit was found histologically or in terms of reepithelialization.78 West and Alster also showed that pretreatment with tretinoin did not significantly affect the rates of post–carbon dioxide laser hyperpigmentation.79 At 3 weeks, retinoids are known to affect only the epidermis, which is completely removed with ablative carbon dioxide resurfacing. Therefore, retinoid pretreatment might prove more advantageous with erbium lasers, fractionated resurfacing, or increased pretreatment duration. However, understandably, there is no effect when a carbon dioxide ablative laser is used after a short pretreatment regimen.

greater than 0.01% applied daily or 0.05% three times weekly.

4. Using conventional dosing regimens, tretinoin-induced changes in the epider­ mis are seen at 3 to 6 months, but dermal changes are not reliably seen until 9 to 12 months.

5. Pretreatment with retinoids (of short duration) before chemical peel and dermabrasion will decrease healing time; however, evidence does not support its use before carbon dioxide laser resurfacing.

6. Retinaldehyde 0.05% to 0.1% is the only over-the-counter retinoid with significant evidence supporting its use. Clinical evidence (without histologic evidence) suggests equivalence to 0.5% tretinoin.

7. Retinol can induce skin rejuvenation at doses in the range of 0.4% to 1.0%; however, most commercial products contain subtherapeutic concentrations (<0.08%).

8. There is no evidence to support the use of retinoids commonly used in cosmeceutical products (e.g., retinyl-palmitate, ­retinyl-propionate, retinyl-acetate).

9. Retinoid therapy does not appear to cause permanent change. Discontinuation of use will cause regression of clinical gains.

Rod J. Rohrich, M.D. University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas, Texas 75390-9132 rod.rohrich@utsouthwestern.edu

PATIENT CONSENT

The patient provided written consent for the use of her images.

REFERENCES

PRACTICAL USE GUIDELINES 1. Tretinoin is the criterion standard for evidence-based retinoid-based skin care therapy.

2. In the first 6 months of therapy, tretinoin should be applied nightly at concentrations of 0.025% to 0.05%. Patients with sensitive skin should be advised to decrease frequency until tolerance to the retinoid reaction has been obtained.

3. Maintenance tretinoin therapy (after 1 year) does not require concentrations

488e

1. Kielbassa C, Epe B. DNA damage induced by ultraviolet and visible light and its wavelength dependence. Methods Enzymol.

2000;319:436–445.

2. Young IS, Woodside JV. Antioxidants in health and disease.

J Clin Pathol. 2001;54:176–186.

3. Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Acquired disorders of elastic tissue: Part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol.

2004;51:1–21; quiz 22.

4. Yeatman JM, Kilkenny M, Marks R. The prevalence of seborrhoeic keratoses in an Australian population: Does exposure to sunlight play a part in their frequency? Br J Dermatol.

1997;137:411–414.

5. Yaar M, Gilchrest BA. Skin aging: Postulated mechanisms and consequent changes in structure and function. Clin Geriatr Med. 2001;17:617–630, v.

Volume 133, Number 4 • Topical Retinoids for Skin Aging 6. El Domayati M, Attia S, Saleh F, et al. Intrinsic aging vs. photoaging: A comparative histopathological, immunohistochemical, and ultrastructural study of skin. Exp Dermatol.

2002; 11:398–405.

7. Reenstra WR, Yaar M, Gilchrest BA. Aging affects epidermal growth factor receptor phosphorylation and traffic kinetics.

Exp Cell Res. 1996;227:252–255.

8. Elias PM, Ghadially R. The aged epidermal permeability barrier: Basis for functional abnormalities. Clin Geriatr Med. 2002;18:103–120, vii.

9. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol.

1979;73:141–143.

10. Montagna W, Hu F, Carlisle K. A reinvestigation of solar lentigines. Arch Dermatol. 1980;116:1151–1154.

11. Lavker RM, Kligman AM. Chronic heliodermatitis: A morphologic evaluation of chronic actinic dermal damage with emphasis on the role of mast cells. J Invest Dermatol. 1988;90:325–330.

12. Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur J Dermatol. 2003;13:515–523.

13. Tanaka H, Okada T, Konishi H, Tsuji T. The effect of reactive oxygen species on the biosynthesis of collagen and glycosaminoglycans in cultured human dermal fibroblasts. Arch Dermatol Res. 1993;285:352–355.

14. Bernstein EF, Uitto J. Connective tissue alterations in photoaged skin and the effects of alphahydroxy acids. J Geriatr Dermatol. 1995;3(Suppl A):7–18A. 15. Kang S, Fisher G, Voorhees JJ. Photoaging: Pathogenesis, prevention and treatment. Clin Geriatr Med. 2001;17:643–659.

16. Kligman AM, Grove FL, Hirose R, et al. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986;15:836–859.

17. Kligman LH. Effects of all-trans-retinoic acid on the dermis of hairless mice. J Am Acad Dermatol. 1986;15:779–785, 884–887.

18. Kligman LH. Connective tissue photodamage in the hairless mouse is partially reversible. J Invest Dermatol. 1984;88:12s–17s.

19. Darlenski R, Surber C, Fluhr JW. Topical retinoids in the management of photodamaged skin: From theory to ­evidence-based practical approach. Br J Dermatol. 2010;163:1157–1165.

20. Duell EA, Astrom A, Griffiths CE, et al. Human skin

levels of retinoic acid and cytochrome P-450-derived ­4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro.

J Clin Invest. 1992;90:1269–1274.

21. Jurzak M, Latocha M, Gojniczek K, et al. Influence of retinoids on skin fibroblasts metabolism in vitro. Acta Pol Pharm.

2008;65:85–91.

22. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest.

2000;106:663–670.

23. Kim HJ, Bogdan NJ, D’Agostaro LJ, et al. Effect of topical retinoic acids on the levels of collagen mRNA during the repair of UVBinduced dermal damage in the hairless mouse and the possible role of TGF-beta as a mediator. J Invest Dermatol. 1992;98:359–363.

24. Woodley DT, Zelickson AS, Briggaman RA, et al. Treatment of photoaged skin with topical tretinoin increases ­epidermal-dermal anchoring fibrils: A preliminary report.

JAMA 1990;263:3057–3059.

25. Griffiths CE, Russman AN, Majmudar G, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med. 1993;329:530–535.

26. Berardesca E, Gabba P, Farinelli N, et al. In vivo

tretinoin-induced changes in skin mechanical properties. ­ Br J Dermatol. 1990;122:525–529.

27. Grove G, Grove M, Zerweck C, et al. Determination of topical tretinoin effects on cutaneous microcirculation in photoaged skin by laser Doppler velocimetry. J Cutan Aging Cosmet Dermatol. 1988;1:27–33.

28. Takahashi N, Fujiu Y. Cytokeratins 16 and 10 bind to retinoic acid covalently in skin tissue of mice. Br J Dermatol.

2010;162:974–979.

29. Weiss JS, Ellis CN, Headington JT, et al Topical tretinoin improves photoaged skin: A double blind vehicle-controlled study. JAMA 1988;259:527–532.

30. Shukuwa T, Kligman AM, Stoudemayer T, et al. The effect of short-term (1 month) topical tretinoin of photodamaged forearm skin. J Dermatol Treat. 1993;4:139–143.

31. Leyden JJ, Grove GL, Grove MJ, et al. Treatment of photodamaged facial skin with topical tretinoin. J Am Acad Dermatol. 1989;21:638–644.

32. Caputo R, Monti M, Motta S, et al. The treatment of visible signs of senescence: The Italian experience. Br J Dermatol.

1990;122(Suppl):97–103.

33. Weinstein GD, Nigra TP, Pochi PE, et al. Topical treti noin for treatment of photodamaged skin. Arch Dermatol.

1991;127:659–665.

34. Bhawan J, Gonzalez-Serva A, Nehal K, et al. Effects of

tretinoin on photodamaged skin: A histologic study. Arch Dermatol. 1991;127:666–672.

35. Olsen EA, Katz HI, Levine N, et al. Tretinoin emollient

cream: A new therapy for photodamaged skin. J Am Acad Dermatol. 1992;26:215–224.

36. Bhawan J, Palco MJ, Lee J, et al. Reversible histologic effects of tretinoin on photodamaged skin. J Geriatr Dermatol.

1995;3:62–67.

37. Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation: A double-blind, vehicle-controlled comparison of 0.1% and ­ 0.025% tretinoin creams. Arch Dermatol. 1995;121:1037–1044.

38. Olsen EA, Katz HI, Levine N, et al. Tretinoin emollient cream for photodamaged skin: Results of 48-week, multicenter, double-blind studies. J Am Acad Dermatol. 1997; 37:217–226.

39. Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0.02% for the treatment of photodamaged facial skin: A review of 2 double-blind clinical trials. Cutis 2001;68:135–142.

40. Kligman DE, Sadiq I, Pagnoni A, Stoudemayer T,Klingman AM. High-strength tretinoin: A method for rapid retinization of facial skin. J Am Acad Dermatol.1998;39:S93–S97.

41. Kligman DE, Draelos ZD. High-strength tretinoin for

rapid retinization of photoaged skin. Dermatol Surg.

2004;30:864–866.

42. Olsen EA, Katz HI, Levine N, et al. Sustained improve ment in photodamaged skin with reduced tretinoin emollient cream treatment regimen: Effect of once-weekly and t­hree-times-weekly applications. J Am Acad Dermatol.

1997;37:227–230.

43. Ellis CN, Weiss JS, Hamilton TA, et al. Sustained improvement with prolonged topical tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol. 1990;23:629–637.

44. Bhawan J, Olsen E, Lufrano L, et al. Histologic evaluation of the long-term effects of tretinoin on photodamaged skin.

J Dermatol Sci. 1996;11:177–182.

45. Kligman AM, Graham GF, Histologic changes in facial skin after daily application of tretinoin for 5 to 6 years. J Dermatol Treat. 1993;4:113–117.

46. Griffiths CE. Drug treatment of photoaged skin. Drugs Aging 1999;14:289–301.

489e

Plastic and Reconstructive Surgery • April 2014 47. Armstrong RB, Lesiewicz J, Harvey G, et al. Clinical panel assessment of photodamaged skin treated with isotretinoin using photographs. Arch Dermatol. 1992;128:352–356.

48. Sendagorta E, Lesiewicz J, Armstong RB. Topical isotretinoin for photodamaged skin. J Am Acad Dermatol. 1992;27s:15–18.

49. Maddin S, Lauharanta J, Agache P, et al. Isotretinoin

improves the appearance of photodamaged skin: Results of a 36-week, multicenter, double-blind, placebo-controlled trial.

J Am Acad Dermatol. 2000;42:56–63.

50. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses.

J Am Acad Dermatol. 1994;30:447–451.

51. Hernandez-Perez E, Khawaja HA, Alvarez TY. Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg. 2000;26:649–652.

52. Kalil CL, Fachinello FZ, Lamb FM, Comunello LN. Use of oral isotretinoin in photoaging therapy. Skinmed 2008;7:10–14.

53. Bagatin E, Parada MO, Miot HA, Hassun KM,Michalany

N, Talarico S. A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol. 2010; 49:207–214.

54. Han HS, Kwon YJ, Park MS, et al. Efficacy validation of synthesized retinol derivatives in vitro: Stability, toxicity, and activity. Bioorg Med Chem. 2003;11:3839–3845.

55. Kurlandsky SB, Xiao JH, Duell EA, Voorhees JJ,Fisher GJ. Biological activity of all-trans retinol requires metabolic conversion to all-trans retinoic acid and is mediated through activation of nuclear retinoid receptors in human keratinocytes. J Biol Chem. 1994;269:32821–32827.

56. Chiu A, Kimball AB. Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. Br J Dermatol. 2003;149:681–691.

57. Piérard-Franchimont C, Castelli D, Cromphaut IV. Tensile properties and contours of aging facial skin: A controlled double-blind comparative study of the effects of retinol, melibose-lactose and their association. Skin Res Technol.

1998;4:237–243.

58. Varani J, Warner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimu­ lates collagen accumulation in naturally aged human skin.

J Invest Dermatol. 2000;114:480–486.

59. Kafi R, Kwak HS, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol.

2007;143:606–612.

60. Dahiaya A, Romano JF. Cosmeceuticals: A review of

their use for aging and photoaged skin. Cosmet Dermatol.

2006;19:479–484.

61. Green C, Orchard G, Cerio R, et al. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoaging. Clin Exp Dermatol. 1998;23:162–167.

62. Watson RE, Long SP, Bowden JJ, Bastrilles JY,Barton SP,

Griffiths CE. Repair of photoaged dermal matrix by topical

490e

application of a cosmetic ‘antiageing’ product. Br J Dermatol.

2008;158:472–477.

63. Lee MS, Lee KH, Sin HS, Um SJ, Kim JW, Koh BK. A newly synthesized photostable retinol derivative (retinyl N-formyl aspartamate) for photodamaged skin: Profilometric evaluation of a 24-week study. J Am Acad Dermatol. 2006;55:220–224.

64. Kim H, Kim N, Jung S, et al. Improvement in skin wrinkles from the use of photostable retinyl retinoate: A randomized controlled trial. Br J Dermatol. 2010;162:497–502.

65. Fort-Lacoste L, Verscheure Y, Tisne-Versailles J, Navarro R. Comedolytic effect of topical retinaldehyde in the rhino mouse model. Dermatology 1999;199(Suppl 1):33–35.

66. Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39:960–965.

67.

Leyden J. Adapalene in clinical practice. Cutis 2001;68(Suppl):7–9.

68. Oda RM, Shimizu RW, Sabatine SC, et al. Effects of structural changes on retinoid cytotoxicity in the CHO clonal assay.

In Vitro Toxicol. 1996;9:173–181.

69. Kligman AM. Guidelines for the use of topical treti noin (Retin-A) for photoaged skin. J Am Acad Dermatol.

1989;21:650–654.

70. Torras H. Retinoids in aging. Clin Dermatol. 1996;14:207–215.

71. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3:641–651.

72. Yamaguchi Y, Nagasawa T, Nakamura N, et al Successful

treatment of photo-damaged skin of nano-scale atRA particles using a novel transdermal delivery. J Control Release 2005;104:29–40.

73. Jick SS, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and congenital disorders.

Lancet 1993;341:1181–1182.

74. Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol.

1991;127:678–682.

75. Mandy S. Tretinoin in the preoperative and postopera tive management of dermabrasion. J Am Acad Dermatol.

1986;15:878–879.

76. McDonald WS, Beasly D, Jones C. Retinoic acid and CO2 laser resurfacing. Plast Reconstr Surg. 1999;7:2229–2235.

77. Duke D, Grevelink JM. Care before and after laser skin resurfacing: A survey and review of the literature. Dermatol Surg.

1998;24:201–206.

78. Orringer JS, Kang S, Johnson TM, et al. Tretinoin treatment before carbon-dioxide laser resurfacing: A clinical and biochemical analysis. J Am Acad Dermatol. 2004;51:940–946.

79. West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. Dermatol Surg. 1999;25:15–17.